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Cindy E. NeunertTreatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the0037-1963
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Seminarsplatelet count and preventing significant hemorrhage even when there is minimal bleeding
present. This approach, however, requires that a large number of patients receive prophylactic
treatment to prevent major bleeding events. Identification of initial risk factors for development
of severe bleeding would allow for more directed and personalized therapy. This review
provides a summary of the current literature with the intent to explore various clinical and
laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and
aspects of platelet function.
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ecently published immune thrombocytope-
nia (ITP) guidelines recommend that chil-
dren with only skin manifestations at
diagnosis can be managed with observation alone1;
however, given concerns about the risk of bleeding
in a child with severe thrombocytopenia, many
physicians still opt for treatment with drug therapy.
The ultimate goal of such prophylactic treatment is
to promptly raise the platelet count and reduce the
perceived risk of subsequent significant bleeding.
Yet, there is a paucity of data to support the use of
drug therapy in this setting, so the decision to treat is
likely affected by personal experiences and attitudes
about the number needed to treat to prevent one
bleeding event.2 More refined risk stratification
models would aid physicians in identifying the
patients who would most benefit from drug therapy,
thus reducing the number needed to treat, and
offering more personalized treatment.
Review of cases of intracranial hemorrhage (ICH)
reported in the literature may provide identification
of common traits among patients. Table 1 shows
pooled data from four case series and one case-
control study of ICH.3–7 The majority of patients had
severe thrombocytopenia, over half had mucosalblished by Elsevier Inc.
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Open access under CC BY-NC-ND license.bleeding, and approximately one third had acute
disease. Additionally, 20% of events were associated
with head trauma. No characteristics either at diag-
nosis or preceding ICH were shown to be inclusive
of all patients. Interpretation of these results is
limited because of the variable data collected across
studies. In addition, these reports do not address
additional forms of severe hemorrhage beyond ICH
and most do not comment on bleeding prior to the
development of ICH but rather only at the time of
the event. Most importantly, only one study contains
a control group of patients without ICH for
comparison.4
Despite having limitations these case series pro-
vide useful evaluation of possible clinical predictors
of severe hemorrhage. For example, mucosal bleed-
ing, ‘‘wet purpura’’ or oral mucosal bleeding have
been presumed to place children at greater risk for
ICH and have historically guided treatment.8 How-
ever, there are no prospective data to suggest this
and the existing retrospective data from the ICH
cases are inconclusive. In the case-control series by
Psaila et al, findings of ‘‘wet purpura’’ were not
clearly related to ICH (27.5% of cases, 19% of
controls).4 The authors did, however find hematuria
to be predictive of ICH, with nine of the 40 patients
with ICH also having gross and microscopic hema-
turia, compared to none in the control group
(Po.001). A limitation of these data is that screen-
ing for microscopic hematuria in the control group
was not known. Additionally, the investigators found
that head trauma occurred with greater frequency in
ICH cases. It is not surprising that head trauma was a
risk factor for ICH; however, it may also represent ap S55–S57 S55
Table 1. Pooled Data on Risk Factors for
Intracranial Hemorrhage3–7
Risk Factor
No. of Cases
(N ¼ 153)*
Platelet counto20 x 109/L 118/127 (93%)
Platelet counto10 x109/L 87/127 (68.5%)
Additional mucosal bleeding 40/61 (65.6%)
At diagnosis 10/17 (60%)
Hematuria 20/105 (19%)
Acute disease 99/147 (67.3%)
Head trauma 29/136 (21.3%)
*There were a total of 153 cases of ICH reported. The
denominator represents the number of cases with the specific
risk factor reported.
C.E. NeunertS56recall bias in questioning and trauma is not suitable
for inclusion in a risk stratification model applied at
diagnosis based on its unpredictability.
Beyond clinical findings, laboratory assessment
may also help to explain bleeding variability. Tradi-
tionally, only the platelet count has been used to
characterize patient risk, with a cutoff ofo20  109/
L generally defining patients with severe disease.
Applying International Cooperative ITP Study Group
(ICIS) Registry II data, a platelet counto20  109/L
had a sensitivity of 88% and specificity of 21% in
differentiating bleeding severity.9 This finding has
been supported by Page et al, who showed that
platelet count was poorly correlated with bleeding
severity at a platelet counto30  109/L.10 While
severe thrombocytopenia appears necessary, as illus-
trated in Table 1, it is not sufficient for the develop-
ment of severe hemorrhage.
It has been hypothesized that antibodies directed
at sites essential for platelet activation and adhesion
may explain the heterogeneity of bleeding symp-
toms. Unfortunately, lack of evidence leaves this
matter unsettled, so the role of anti-platelet anti-
bodies in inducing abnormal platelet function in
patients with ITP is not well established.11–13 Few
investigations have explored the link between plate-
let function, anti-platelet antibodies, and the clinical
outcome of bleeding severity. Panzer et al found that
neither platelet function, based on platelet p-selectin
levels, nor positivity for anti-platelet antibodies was
correlated with bleeding severity (P4.05).12 Addi-
tionally platelet function assessment using the cone
and platelet analyzer was performed and surface
coverage inversely correlated with bleeding severity
(odds ratio [OR] 0.45; 95% confidence interval [CI],
0.17–0.87; P ¼ .04). They concluded that the
majority of patients with ITP have highly activated
platelets that are able to form platelet aggregates
compensating for reduced platelet numbers. An
inability for platelet activation to occur in a selectgroup of patients with ITP may be partially respon-
sible for development of severe hemorrhage. Micro-
particles, procoagulant vesicles released from
platelets, may also play a role in maintaining hemo-
stasis in ITP and explain why the majority of patients
with ITP can endure very low platelet counts with-
out significant hemorrhage. Results from two studies
propose that patients with higher platelet micro-
particle levels experienced less bleeding.14,15 More
conclusive studies of laboratory risk factors may
be difficult to carry out because of the rarity of
severe bleeding, difficulty in assessing platelet
function in patients with thrombocytopenia, and
the poor sensitivity, specificity, and variability of
such testing.
The role of other components of hemostasis,
including vascular integrity and levels of coagulation
factors, on the risk for severe bleeding in ITP remain
understudied. Recent work in a thrombocytopenic
mouse model clearly demonstrated that mice
develop a greater degree of hemorrhage at sites
where significant inflammation was induced.16 This
supports the theory that platelets are essential in
maintaining vascular integrity and that inflammation
predisposes to increased hemorrhage. This work has
been directly translated to patients showing thinning
of the endothelium in patients with thrombocytope-
nia and cessation of bleeding prior to an increase in
platelet count related to closing of endothelial gap
junctions.17 Another possible source of bleeding in
patients with ITP could be a coexisting hemostatic
alteration that had otherwise been clinically silent. A
major determinant of primary hemostasis, in addition
to the platelet count, is the amount and functional
activity of von Willebrand factor. This adhesive
glycoprotein anchors platelets to the injured vessel
wall. It is possible that a ‘‘two-hit’’ process results in
clinical bleeding with ITP in those with low von
Willebrand factor activity.
As outlined above, several factors appear to be
permissive but not sufficient for development of
significant hemorrhage, including severe thrombocy-
topenia, additional mucosal bleeding, and head
trauma. Therefore, ideally several factors would need
to be included in further studies of risk prediction.
When assessing the value of a prediction model,
thresholds for sensitivity, specificity, and positive
and negative predictive value need to be well
established to be clinically useful and adapted by
physicians. For example, one study combining risk
factors of bleeding beyond skin, and/or head trauma,
and/or a platelet counto10  109/L yielded a
sensitivity of 100% but specificity of only 23%.4 In
this model, a significant number of children would
need to be treated to prevent an episode of ICH. The
authors then refined the predictors to the more
specific markers of hematuria and/or head trauma
Individualized treatment for ITP S57identified by comparing cases and controls. While
the specificity increased to 99% it was at the expense
of a sensitivity of 50%.4 In this case, fewer patients
receive prophylactic therapy unnecessarily; how-
ever, a few cases at high risk of developing ICH
would not be identified early nor appropriately
treated. Physician experience may dictate acceptable
thresholds for sensitivity and specificity regardless of
the evidence, so uniform agreement on the number
needed to treat may be difficult to achieve.2
In conclusion, in it is unlikely that a single
predictive factor will determine patients with ITP
at risk for severe bleeding. Rather, risk of major
hemorrhage is likely multifactorial and different for
each patient, eg, in some patients severe hemor-
rhage is related to an unpredictable traumatic event
regardless of additional factors that may be present.
To better define a prediction model for risk factors of
severe hemorrhage, prospective cohorts should
focus on inconclusive assessment of all risk factors
at diagnosis and provide detailed bleeding assess-
ment using rigorous bleeding scales at all visits.
While the addition of comprehensive laboratory
testing maybe useful, refinement of such testing
and its application to clinical practice makes it
limited at present. Application of uniform treatment
with observation for patients with no or mild bleed-
ing and severe thrombocytopenia will expand our
knowledge about those rare children who subse-
quently develop significant hemorrhage.
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